Reuters logo
India's Sun Pharma to buy Dusa for $230 mln
November 8, 2012 / 11:57 AM / 5 years ago

India's Sun Pharma to buy Dusa for $230 mln

Nov 8 (Reuters) - India’s Sun Pharmaceutical Industries Ltd said it will acquire U.S. dermatology company Dusa Pharmaceuticals Inc for about $230 million to gain access to its light-based skin treatment platform.

Dusa shareholders will get $8 per share in cash, representing a 38 percent premium to Dusa’s Wednesday stock close.

Dusa was advised by Leerink Swann on the deal, the companies said in a joint statement. (Reporting by Esha Dey in Bangalore; Editing by Roshni Menon)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below